Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Certara Inc.

Certara ( ($CERT) ) has shared an update. On May 14, 2026, Certara, Inc. held its annual meeting of stockholders, where investors elected three Cla...

Certara Shareholders Back Directors, Auditor and Executive Pay

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Certara (CERT) and Dyne Therapeutics (DYN) with bull...

Analysts Offer Insights on Healthcare Companies: Certara (CERT) and Dyne Therapeutics (DYN)

Analysts fell to the sidelines weighing in on Certara (CERT) and Gilead Sciences (GILD) with neutral ratings, indicating that the experts are neith...

Analysts’ Top Healthcare Picks: Certara (CERT), Gilead Sciences (GILD)

Certara ( ($CERT) ) has shared an update. Certara reported first‑quarter 2026 revenue of $106.9 million, up 1% year on year, with software revenue ...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CERT	$5.67	+5.98%	3.51M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CERT	$5.67	+6.0%	3.51M
3
4
5
6

CERT

CERT

Dividend Overview

Get Certara Inc. Data in Excel

Get Certara Inc. Data in Excel